The three-year extension contract includes the legal conditions related to the cooperation that has been ongoing since 2015. Beactica CEO Dr Per Kollblad said: “We are pleased to extend our agreement with Sanofi and look forward to continuing our successful collaboration. Sanofi has renewed its master service contract with Swedish pharmaceutical research company Beactica to characterize the interactions between new therapeutic drugs and their target proteins. As part of the partnership, Beactica scientists worked with Sanofi on the analysis of kinetics that occurs when insulin analogues interact with their two binding sites throughout the insulin receptor. Founded in 2006, Beactica uses internal methods to study molecular interactions for the development of new therapeutic drugs. “It is very useful to see tangible evidence of how Beactica`s know-how and skills contribute to products that increase the quality of life of patients with reduced health conditions.” The company also implements drug research programs to address unmet medical needs and allows collaborations to create fragmentation leads through its discovery platform. The findings of this alliance would have contributed to the regulatory approval of Sanofi`s fast-acting insulin lispro Sanofi. Beactica has partnered with a number of pharmaceutical and biotech companies, including Boehringer Ingelheim and Janssen Research and Development, a subsidiary of Johnson and Johnson. ..